학술논문
Innate and Adaptive Cell-Mediated Immune Responses to a COVID-19 mRNA Vaccine in Young Children.
Document Type
Academic Journal
Author
Weinberg A; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Johnson MJ; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Garth K; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Hsieh EWY; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Department of Microbiology and Immunology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Kedl R; Department of Microbiology and Immunology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Weiskopf D; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA.; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, California, USA.; Cassaday M; Department of Microbiology and Immunology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Rester C; Department of Microbiology and Immunology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Cabrera-Martinez B; Department of Microbiology and Immunology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Baxter RM; Department of Microbiology and Immunology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Levin MJ; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Source
Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045 Publication Model: eCollection Cited Medium: Print ISSN: 2328-8957 (Print) Linking ISSN: 23288957 NLM ISO Abbreviation: Open Forum Infect Dis Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2328-8957
Abstract
Background: There is little information on cell-mediated immunity (CMI) to COVID-19 mRNA vaccines in children. We studied adaptive and innate CMI in vaccinated children aged 6 to 60 months.
Methods: Blood obtained from participants in a randomized placebo-controlled trial of an mRNA vaccine before and 1 month after the first dose was used for antibody measurements and CMI (flow cytometry).
Results: We enrolled 29 children with a mean age of 28.5 months (SD, 15.7). Antibody studies revealed that 10 participants were infected with SARS-CoV-2 prevaccination. Ex vivo stimulation of peripheral blood mononuclear cells with SARS-CoV-2 spike peptides showed significant increases pre- to postimmunization of activated conventional CD4+ and γδ T cells, natural killer cells, monocytes, and conventional dendritic cells but not mucosa-associated innate T cells. Conventional T-cell, monocyte, and conventional dendritic cell responses in children were higher immediately after vaccination than after SARS-CoV-2 infection. The fold increase in CMI pre- to postvaccination did not differ between children previously infected with SARS-CoV-2 and those uninfected.
Conclusions: Children aged 6 to 60 months who were vaccinated with a COVID-19 mRNA vaccine developed robust CMI responses, including adaptive and innate immunity.
Competing Interests: Potential conflicts of interest. A. W. is a consultant for Pfizer. D. W. is a consultant for Moderna. M. J. L. is a consultant for Moderna and Pfizer. The La Jolla Institute for Immunology has filed for patent protection for various aspects of the T-cell epitope and vaccine design work. All other authors report no potential conflicts.
(© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Methods: Blood obtained from participants in a randomized placebo-controlled trial of an mRNA vaccine before and 1 month after the first dose was used for antibody measurements and CMI (flow cytometry).
Results: We enrolled 29 children with a mean age of 28.5 months (SD, 15.7). Antibody studies revealed that 10 participants were infected with SARS-CoV-2 prevaccination. Ex vivo stimulation of peripheral blood mononuclear cells with SARS-CoV-2 spike peptides showed significant increases pre- to postimmunization of activated conventional CD4+ and γδ T cells, natural killer cells, monocytes, and conventional dendritic cells but not mucosa-associated innate T cells. Conventional T-cell, monocyte, and conventional dendritic cell responses in children were higher immediately after vaccination than after SARS-CoV-2 infection. The fold increase in CMI pre- to postvaccination did not differ between children previously infected with SARS-CoV-2 and those uninfected.
Conclusions: Children aged 6 to 60 months who were vaccinated with a COVID-19 mRNA vaccine developed robust CMI responses, including adaptive and innate immunity.
Competing Interests: Potential conflicts of interest. A. W. is a consultant for Pfizer. D. W. is a consultant for Moderna. M. J. L. is a consultant for Moderna and Pfizer. The La Jolla Institute for Immunology has filed for patent protection for various aspects of the T-cell epitope and vaccine design work. All other authors report no potential conflicts.
(© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)